whatsapp-icon : +91 98208 00187  |  Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


  • Dr. Rajput Vice President
  • Regenerative Medicine 1-2
  • Regenerative Medicine 3-5
  • Musculoskeletal Diseases
  • Neurological Diseases
  • Cancer
  • Metabolic and life style diseases & Cardiopulmonary Diseases
  • Processing Bone Marrow
  • 3rd UPOA 2017 1
  • 3rd UPOA 2017 2
  • 3rd UPOA 2017 3
  • International Conference 1
  • International Conference 2
  • International Conference 3
  • latter
  • Stem Cell Injections for Arthritis Knee



  • Stem Cell India Mumbai
  • Stem Cell Treatment In India
  • Stem Cell Therapies 1
  • Indian Journal of Stem Cell Therapy

Welcome To Stem Cell India - Dr. Rajput's OSRC

Dr. Rajput is a consultant orthopaedics and stem cell transplant surgeon practicing for the last 33 years. He has been trained in orthopaedic surgery and stem cell transplantation at various national and international medical centres of repute. He has also received specialised training at Royal Liverpool University Hospital, Liverpool, U.K. Read more...

Dr. Rajput's OSRC

Call : +91 9820850187

Add: 2, Rupa Adarsh Soc., Saraswati Lane, Santacruz (W), Mumbai.

Criticare Hospital

Call   :  +91-22-6775 6600

Add: Main Gulmohar Rd., Juhu, Andheri (W), Mumbai 49.





modunol modunol

  1. Media
  2. Modunol
  3. Photo Gallery



Patient's Testimonials of Dr. Rajput

You must have the Adobe Flash Player installed to view this player.

News & Updates at Stem Cell India

Press Release



Trials show promise for patients with spinal cord injuries Featured

By MaryLynn Schiavi
Special to the Home News Tribune

This monthly column explores ideas, insights and discoveries made in New Jersey that are shaping our future.

The body has extraordinary self healing capabilities, and one New Jersey researcher is building on nature’s regenerative powers with the development of a new delivery system designed to increase the effectiveness and safety of stem cell therapy for spinal cord injuries and other regenerative medicine applications.

The StemCell Bag™ is a new method for reintroducing healthy adult stem cells into the body to regenerate spinal nerves in patients with spinal cord injuries often caused by severe traumas from car accidents and sports injuries.

Using adult stem cells that are derived from the patient’s own body, as opposed to the more controversial embryonic stem cells, which are developed in vitro, Dr. Hatem Sabaawy, founder of Celvive, is delighted with the results of clinical trials conducted on patients in an international study.

“The outcome has been amazing. Many of the patients were confined to their beds and wheelchairs, unable to walk. As a result of the treatment, one out of two patients regained sensation and improved motor improvement and were able to regain mobility,” said Sabaawy, an assistant professor of medicine in the medical oncology division at UMDNJ Robert Wood Johnson Medical School and the Cancer Institute of New Jersey in New Brunswick.

He said the overall response rate was that 23 out of 50 patients, or 46 percent, showed neurological improvements, and many of the 23 patients were able to walk with canes.

Sabaawy said the first phase of the trial was not designed to produce motor gain enabling patients to walk, but rather to test the safety of cell therapy; therefore, a fixed cell dose was given to all 50 patients that had different injuries. The next trial will involve a dose escalation study and will evaluate motor responses and walking, he said.

Harnessing power of adult stem cells
The challenge to utilizing adult stem cells has been the threat of contamination of the cells between the time they are withdrawn from the body and then reintroduced.

The new technology makes it possible to deliver bone marrow cells from the hips of spinal cord-injury patients directly to the patient’s injury site by passing them through the Stem Cell Bag, which is a sealed multiple-bag device. Sabaawy explained that the material of the bag is similar to material currently used in blood bags and does not interact with human cells.

“What we’ve done is to create a closed system to minimize the introduction of pathogens so the cells are not exposed to outside chemicals or agents,” said Reza Razavi, acting chief scientific officer and interim chief executive officer of Celvive, a Delaware-based company with offices in New Brunswick.

Razavi is also director of New Ventures and Strategic Initiatives at Foundation Venture Capital Group, based in New Brunswick. Celvive has secured a preseed investment of up to $500,000 from FVCG to further develop its technology.

Based on the promising results from the Cairo University study, Sabaawy is expecting to move forward with clinical trials in the United States within two years.

Adult vs. embryonic stem cells
According to Sabaawy and Razavi, using adult stem cells as opposed to embryonic is preferable for a number of reasons. In addition to the ethical and moral debate over the use of embryonic cells, their strength is also their weakness. “Because embryonic stem cells can differentiate into all types of tissue, they can also grow tumors,” Sabaawy said.

He said a great deal of research is still needed to determine how to safely use embryonic stem cells, but currently there is no evidence that adult stem cells produce tumors if they have not been manipulated or contaminated in some way.

He also said there are virtually no side effects involved in the outpatient procedure other than temporary pain or swelling at the injection site and/or a headache. To read the results of the study, visit http://bit.ly/15tIFRp.

Last modified on Wednesday, 13 September 2017 06:56
Rate this item
(0 votes)

What our patients says?

Other Patients
1000 characters left